Венетоклакс в клинических исследованиях
- Авторы: Бялик Т.Е1
-
Учреждения:
- Первый МГМУ им И.М. Сеченова (Сеченовский Университет)
- Выпуск: № 12 (2018)
- Страницы: 81-84
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/295834
- DOI: https://doi.org/10.18565/pharmateca.2018.12.81-84
- ID: 295834
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
Венетоклакс - низкомолекулярный селективный ингибитор белка BCL-2. Препарат высокоэффективен при лечении различных онкогематологических заболеваний. В обзоре приведены данные значимых клинических исследований по изучению эффективности и безопасности венетоклакса. В настоящее время проводятся рандомизированные исследования III фазы по изучению комбинаций VEN с различными противоопухолевыми препаратами при многих заболеваниях кроветворной и лимфоидной тканей, и, возможно, после получения результатов будут изменены подходы к терапии этих болезней.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
Т. Е Бялик
Первый МГМУ им И.М. Сеченова (Сеченовский Университет)
Email: bialik@bk.ru
ассистент кафедры онкологии
Список литературы
- Seymour J.F., Davids M.S., Pagel J.M., et al. Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti- Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood 2013;122:872.
- Roberts A.W., Davids M.S., Pagel J.M., et al. S1146; EHA; Stockholm. 2013;13-6.
- Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet. Oncol. 2016;17:768-78. doi: 10.1016/S1470-2045(16)30019-5.
- Stilgenbauer S., Eichhorst B., Schetelig J., et al. Venetoclax for PatientsWith Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol. 2018;36:1-8. doi: 10.1200/JCO.2017. 76.6840
- Jones J., Choi M.Y., Mato A.R., et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood. 2016;128:abstract 637.
- Jones J.A., Mato A.R., Wierda W.G., et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;65-75. doi: 10.1016/S1470-2045(17)30909-9.
- AbbVie. Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation [press release].
- Eichhorst B., Robak T., Montserrat P., et al. Chronic Lymphocytic Leukaemia Treatment Recommendations, Published: 27 June 2017. Authors: ESMO Guidelines Committee, Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26(5): 78-84.
- Seymour J.F., et al. Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. 59TH Annual meeting and exposition of the american society of hematology. Blood 2017;130:LBA-2.
- AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia [press release]. AbbVie. 2018.
- Touzeau C., Dousset C., Le Gouill S., et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210-12. doi: 10.1038/leu.2013.216.
- Kumar S., Kaufman J.L., Gasparetto C., et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401 409. doi: 10.1182/blood-2017-06-788786
- Moreau P, Chanan-Khan A., Roberts A.W., et al. Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma. Blood. 2016;128:975. doi: 10.1182/blood-2017-06-788323.
- Pan R., Hogdal L.J., Benito J.M., et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell. death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362-75. doi: 10.1158/2159-8290. CD-13-0609.
- Konopleva M., Pollyea D.A., Potluri J., et al. Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106-17.
- DiNardo C.D., Pratz K.W., Letai A., et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216-28. doi: 10.1016/S1470-2045(18)30010-X.
- Wei A., Strickland S.A., Roboz G.J., et al. Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcome. Blood. 2017;130:890.
Дополнительные файлы
![](/img/style/loading.gif)